- Home
- AUID vs IMAB Comparison
AUID vs IMAB Comparison
Compare AUID & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUID
- IMAB
- Stock Information
- Founded
- AUID 2009
- IMAB 2014
- Country
- AUID United States
- IMAB United States
- Employees
- AUID N/A
- IMAB N/A
- Industry
- AUID Computer Software: Prepackaged Software
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- AUID Technology
- IMAB Health Care
- Exchange
- AUID Nasdaq
- IMAB Nasdaq
- Market Cap
- AUID 74.1M
- IMAB 200.9M
- IPO Year
- AUID N/A
- IMAB 2020
- Fundamental
- Price
- AUID $3.88
- IMAB $2.13
- Analyst Decision
- AUID
- IMAB Strong Buy
- Analyst Count
- AUID 0
- IMAB 3
- Target Price
- AUID N/A
- IMAB $6.33
- AVG Volume (30 Days)
- AUID 132.6K
- IMAB 621.1K
- Earning Date
- AUID 08-07-2025
- IMAB 05-15-2025
- Dividend Yield
- AUID N/A
- IMAB N/A
- EPS Growth
- AUID N/A
- IMAB N/A
- EPS
- AUID N/A
- IMAB N/A
- Revenue
- AUID $1,025,363.00
- IMAB N/A
- Revenue This Year
- AUID N/A
- IMAB N/A
- Revenue Next Year
- AUID N/A
- IMAB N/A
- P/E Ratio
- AUID N/A
- IMAB N/A
- Revenue Growth
- AUID 230.96
- IMAB N/A
- 52 Week Low
- AUID $3.68
- IMAB $0.60
- 52 Week High
- AUID $10.95
- IMAB $3.08
- Technical
- Relative Strength Index (RSI)
- AUID 33.95
- IMAB 50.03
- Support Level
- AUID $4.80
- IMAB $2.05
- Resistance Level
- AUID $5.71
- IMAB $2.41
- Average True Range (ATR)
- AUID 0.53
- IMAB 0.34
- MACD
- AUID -0.09
- IMAB -0.08
- Stochastic Oscillator
- AUID 11.04
- IMAB 13.68
About AUID authID Inc.
AuthID Inc is a company engaged in ensuring cyber-savvy enterprises Know Who's Behind the Device, for every customer or employee login and transaction. Through its easy-to-integrate, patented, biometric identity platform, authID quickly and accurately verifies a user's identity, eliminating any assumption of who is behind a device and preventing cybercriminals from taking over accounts. authID combines digital onboarding, biometric password less authentication and account recovery, with a fast, accurate, user-friendly experience-delivering identity verification.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).